Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Track 11 Collaboration and Externalization in R&D @ BioIT World, April 30, 2014 Seaport World Trade Center, Boston, MA

Reporter: Aviva Lev-Ari, PhD, RN

Collaboration and Externalization in R&D

4:00 Co-Presentation: Informatics Paradox: Separating and Collaborating in Life Science

Sarah Blendermann, Senior Director, Chemistry & Pharmacology, Business

Technology, Pfizer

Rick Somes, Senior Director, Acquisitions, Divestitures and Restructuring

R&D Business Technology, Pfizer

The organization was running operations and discovery while separating data and systems. Collaboration and segregation were key components of

the informatics required to successfully meet an IPO timeline. A long-term collaboration agreement means ties between the organizations will remain,

requiring longer-term technical solutions for granular security, collaboration, and data sharing.

In REAL TIME

Possibilities:

Sell a sunsidiary for Animal health

IPO

Spin off a subsidiary

Key issues for R%D – 70% of applications, 800 applications between Whole Pfizer and Animal Health.

COLLABORATE

Build a Plan

Thinks to consider 0 Have a documen: Data, people, IT resources

• Application Separation
• License Separations – Vendors: SAS, 800 applications in the postfolio
• Data sepation:
• Compound Inventory – Legal Agreements
• FDA Library
• sales complexity
• IPO complexity -Hard

Begin Separation

• IPO day
• Separation day Zoetis vs. Pfizer
• Application Separation: Human Health vs Animal Health
• Transition Services Agreement – to support shared Applications
• Data Separations Research Commom Compound
• IP, who own experimental research data
• Encumbrances: Collaborations
• Legal agreements
• Collaborations Application to share data

Two separate companies, Partnering on Enchanting future PROVENANCE Issues

4:30 Towards the Intelligent and Automated Analytical Laboratory

Dave Hartsough, Ph.D., Executive Director, Sites, Benchtop, & Validation R&D Informatics, Amgen

This presentation will provide an update on the progress of the Allotrope Foundation towards delivering an open Framework solution for managing analytical data throughout its lifecycle and will include details on the deliverables, timelines, and results from completed proof-of-concept applications based upon the initial proposal and analysis presented in 2013.

Dave Hartsough in REAL TIME

Data id MOST valuable asset

If 3% error rate it addds 30% more cost

EMPLOYEES are the most valuable not data

ALLOTROPE: A foundation 

• Subject matter experts
• Osthus – s Gernam company
• Secretairiate

SW incomplete, no standard formats, incompatible Metadata

Effects: Need for a Framework

Solution Automated documents

• open documents standard – existing standards
• Metadata Repository
• Reusable SW componenets

Ready for archiving

Proof-of-Concept applications (2014)

PoC Instruent SW Integration, PoC Archive, Metadata repository, PoC Viewer

Heading up toward:  Being SOurce agnostict

• Commercial ELN/LIMS,
• Commercial Archive
• Commercial Viewer

GOAL: Reduce cost of interaction with CRO

Example: One instance of one workflow: 20,000 hours per year saving, increasing accuracy, quality of data

First PoC deployed to one of member company

BENEFITS OF BEING A MEMBER IN THIS INTERNATIONAL CONSORTIUM

Instrument & software Vendors

http://partners.alllotrope.org

Regulatory engagement FDA Liaison to be assign to work wiht the Consorsium.

Access data complexity – reduced

Framework is based on dtandard

www.allotrope .org

 

ROI

 

5:00 Growing our Innovation Capability from the Inside-Out: AstraZeneca’s Journey to a New a Way of Working

Scott Wilkins, Ph.D., Enterprise Innovation Director, AstraZeneca

Scott Wilkins in REAL TIME

$4 billion spent on R&D every year

25 Billion in Sales

Partnering and collaborations are KEY

21 century- NETWORKS are key to survival

Use R&D  resources and Collaborations

 

2010 – R&D Culture Initiatives – Professional skills, communications, grow collaborative behaviors

2011 – Evaluated and Piloted R&D Collaborations tools Globally enterprise -wide R&D

2012 0 Innovation Capabilities: Culture, technology, partners, Processes

Information Pyramid

InnoCENTIVE -consuting with NASA

• iSOLE Coach
• Challenge Owner
• Solver evaluation & Award

2012 – 5,000 participants in Challenges launched, 500 ideas, $1 million Awarded to Winners

Enterprise Collaboration

OUTCOMES: Going to AstraZeneca OPEN Innovations 10,000 Scientists around the glovbr

• New molecule Profiling
• Novel Disease Indications for AstraZeneca Competition